FUSION DIAGNOSTIC LABORATORIES, LLC. v. ATILA BIOSYSTEMS, INC.

CourtDistrict Court, D. New Jersey
DecidedJune 17, 2024
Docket2:24-cv-00184
StatusUnknown

This text of FUSION DIAGNOSTIC LABORATORIES, LLC. v. ATILA BIOSYSTEMS, INC. (FUSION DIAGNOSTIC LABORATORIES, LLC. v. ATILA BIOSYSTEMS, INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
FUSION DIAGNOSTIC LABORATORIES, LLC. v. ATILA BIOSYSTEMS, INC., (D.N.J. 2024).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

FUSION DIAGNOSTIC LABORATORIES, LLC, Civ. No. 2:24-ev-00184 (WJM) Plaintiff, OPINION Vv. ATILA BIOSYSTEMS, INC. Defendant.

In this breach of contract action, Defendant Atila Biosystems, Inc. (“Defendant”) moves to dismiss the Complaint pursuant to Fed. R. Civ. P. 12(b)(6) for failure to state a claim upon which relief may be granted. ECF No. 11. The Court decides the matter without oral argument. Fed. R. Civ. P. 78(b). For the reasons stated below, Defendant’s motion to dismiss is GRANTED IN PART AND DENIED IN PART. 1 BACKGROUND Plaintiff Fusion Diagnostic Laboratories, Inc. (‘Plaintiff’) is a New Jersey independent clinical laboratory that offers diagnostic testing services, including SARS- CoV-2 (“Covid” or “Covid-19”) testing. Compl. § 1. Defendant is a California based manufacturer and supplier of laboratory instruments, reagents, consumables, software, and supplies. Id. at | 2. Among the products Defendant markets and sells are Covid testing kits and instruments including the Atila Power Gene 9600 Plus Real Time PCR System (“Analyzer”) and iAMP Covid-19 Detection Kit (“Covid Kit”). fd. at ¥ 2. □ From about September 28, 2020 to January 9, 2022, Plaintiff paid Defendant a total of $938,800 for the Analyzer and several lots of Covid Kits. fd. at {J 7, 19. Each Covid Kit contained materials for 100 tests. Jd. at ¢ 18. On December 21, 2021, Plaintiff recetved Lot 16 (150 Covid Kits), id at § 21, which purportedly had “irregularities” including false positive test results, inconsistent measurements of controls, and an inordinate amount of invalid results. /d. at {J 27-28. Plaintiff notified Defendant of these irregularities, but Defendant claimed the problem was contamination at Plaintiff's lab or Plaintiff's failure to follow testing protocol. Jd. at 30. On January 5, 2022, Plaintiff received Lot 31 (200 Covid Kits), ia. at | 23, which it alleges yielded “high” positive results, See id. at Yj 36- 68. Due to the defective kits, Plaintiff was not able to “release the test results which severely and irreparably damaged its reputation with Hoboken, Bayonne and Union City” ]

and was immediately banned from those and other sites, Jd, at {41. After conducting testing on Lot 31, on February 19, 2022, Defendant refunded Plaintiff the Lot 31 purchase price of $319,800. Jd, at 7 69. Plaintiff filed suit on January 11, 2024 seeking $30 million compensatory and punitive damages for loss of business and profits from “extensive” damage to its business reputation. The Complaint pleads breach of contract (Count I), breach of express warranty (Count ID), and negligent misrepresentation (Count II}. ECF No. 1. Defendant moves to dismiss the Complaint on the grounds that 1) it is immune from liability under the Public Readiness and Emergency Preparedness Act, 42 U.S.C. §§ 247d-6d, 247d-6e (“PREP Act”); 2) Plaintiff fails to identify the contract or warranties that have been breached; 3) New Jersey’s economic loss doctrine bars the claim for negligent misrepresentation; and 4) the Complaint does not support a claim for punitive damage. Il. DISCUSSION A. Motion to Dismiss Standard Federal Rule of Civil Procedure 12(b)(6) provides for the dismissal of a complaint, in whole or in part, if the plaintiff fails to state a claim upon which relief can be granted. The moving party bears the burden of showing that no claim has been stated. Hedges vy. United States, 404 F.3d 744, 750 3d Cir.2005), Dismissal is appropriate only if, accepting all the facts alleged in the complaint as true, the plaintiff has failed to plead “enough facts to state a claim to relief that is plausible on its face.” Bell Atl, Corp. v. Twombly, 550 U.S, 544, 570 (2007); see also Umland v. PLANCO Fin. Serv., Inc., 542 F.3d 59, 64 Gd Cir. 2008). This assumption of truth is inapplicable, however, to legal conclusions couched as factual allegations or to “[t]hreadbare recitals of the elements of a cause of action, supported by mere conclusory statements.” Ashcroft v. Iqbal, 556 U.S. 662 (2009). That is, although a complaint need not contain detailed factual allegations, “a plaintiff's obligation to provide the ‘grounds’ of his ‘entitlement to relief’ requires more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do.” Twombly, 550 U.S. at 555. Thus, the factual allegations must be sufficient to raise a plaintiffs right to relief above a speculative level, see id. at 570, such that the court may “draw the reasonable inference that the defendant is liable for the misconduct alleged.” Iqbal, 556 U.S. at 678 (citing Twombly, 550 U.S. at 556). While “[t]he plausibility standard is not akin to a probability requirement .., it asks for more than a sheer possibility that a defendant has acted unlawfully.” /gbal, 556 U.S. at 678. B. Immunity Under PREP Act “The PREP Act protects certain covered individuals—such as pharmacies and drug manufacturers—from lawsuits during a public-health emergency.” Maglioli v. Alliance HC Holdings LLC, 16 F Ath 393, 400 Gd Cir. 2021); 42 U.S.C. § 247d-6d(i)(2). If the Secretary

of the Department of Health and Human Services (the “Secretary”) “deems a health threat a public-health emergency, he may publish a declaration in the Federal Register recommending certain ‘covered countermeasures.’” Maglioli, 16 F.4 at 400 (citing 42 U.S.C. § 247d-6d(b)(1)). “Covered countermeasure” includes a drug, biological product, ot device authorized for emergency use. 42 U.S.C. § 247d-6d (i)(1)(C). In March 2020, the Secretary declared Covid-19 a public-health emergency and recommended a series of covered countermeasures. Maglioli, 16 F.4" at 401 (citing Declaration Under the PREP Act for Medical Countermeasures Against COVID-19 (“Declaration”), 85 Fed. Reg. 15,198, 15,201, 15,202 (Mar. 17, 2020)). Once the PREP Act is invoked by the Secretary, a “covered person” is immune from “suit and liability under Federal and State law with respect to all claims for loss caused by, arising out of, relating to, or resulting from the administration to or the use by an individual of a covered countermeasure,” 42 U.S.C. § 247d-6d(a)(1) (emphasis added), except for claims of “willful misconduct” as defined in the PREP Act, § 247d-6d (d)(1). Immunity under this subsection applies to “any claim for loss that has a causal relationship with the administration to or use by an individual of a covered countermeasure.”” Id. at § 247d- 6d(a)\(2)(B) (emphasis added). Where the PREP Act applies, the scope of immunity is broad. Maglioli, 16 F.4" at 401. Plaintiff does not dispute that Defendant is a “covered person” or that its Covid tests are “covered countermeasures,” but is correct that Defendant is not immune under the PREP Act from Plaintiff's state law breach of contract claims.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hercules, Inc. v. United States
516 U.S. 417 (Supreme Court, 1996)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Umland v. PLANCO Financial Services, Inc.
542 F.3d 59 (Third Circuit, 2008)
Sandler v. Lawn-A-Mat Chem. & Equip. Corp.
358 A.2d 805 (New Jersey Superior Court App Division, 1976)
Troy v. Rutgers
774 A.2d 476 (Supreme Court of New Jersey, 2001)
Alloway v. General Marine Industries, L.P.
695 A.2d 264 (Supreme Court of New Jersey, 1997)
Spring Motors Distributors, Inc. v. Ford Motor Co.
489 A.2d 660 (Supreme Court of New Jersey, 1985)
ARLANDSON v. Hartz Mountain Corp.
792 F. Supp. 2d 691 (D. New Jersey, 2011)
Bracco Diagnostics Inc. v. Bergen Brunswig Drug Co.
226 F. Supp. 2d 557 (D. New Jersey, 2002)
Daloisio v. Liberty Mutual Fire Insurance
754 F. Supp. 2d 707 (D. New Jersey, 2010)
Naporano Iron & Metal Co. v. American Crane Corp.
79 F. Supp. 2d 494 (D. New Jersey, 2000)
Laura Fabbro v. DRX Urgent Care LLC
616 F. App'x 485 (Third Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
FUSION DIAGNOSTIC LABORATORIES, LLC. v. ATILA BIOSYSTEMS, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/fusion-diagnostic-laboratories-llc-v-atila-biosystems-inc-njd-2024.